Company / Capital Expenditures
Protara Therapeutics, Inc. Capital Expenditures History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$51.0K
FY2016
5-year range
$10.0K / $67.0K
FY2014-FY2016
Trend
+410.0%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +410% YoY in FY2016, a notable deviation from the 2-year average annual change of +162%.
Based on SEC 10-K filings.
$51,000 in FY2016.
Declined from $67,000 to $51,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, capital expenditures increased 410.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $51.0K | +410.0% |
| FY2015 | $10.0K | -85.1% |
| FY2014 | $67.0K | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026